Posts by: Santiago Gisler

News

Feeding black tea extract to mice in models of pulmonary fibrosis (PF) lessened several disease-associated fibrotic markers, a recent study found. The results suggest black tea extract may have a ... Read more

February 8, 2019February 13, 2019

Interactive Platform Guides PF Patients, Connects Them with Healthcare Providers, Family

News

A new online platform that pulmonary fibrosis (PF) patients, their friends, family, and caretakers to connect and get information about the disease, was launched recently by the Pulmonary Fibrosis Foundation (PFF) ... Read more

February 1, 2019February 7, 2019

Actigraphy is Clinically Meaningful Tool in PH-IPF Patients Treated with iNOpulse

News

Results of a Phase 2b clinical trial suggest actigraphy as a relevant tool to detect meaningful clinical changes in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) ... Read more

January 22, 2019January 22, 2019

Oral IPF Candidate Targeting LOXL2 Protein May Move into Phase 2 Trials

News

Synairgen announced it successfully completed three-month toxicity studies on LOXL2 (lysyl oxidase like 2) inhibitor candidates for treating idiopathic pulmonary fibrosis (IPF). The LOXL2 program, developed in collaboration with ... Read more

January 16, 2019January 21, 2019

Senolytic Treatment Improves Physical Function in IPF Patients, According to Small Pilot Study

News

A small Phase 1 pilot study found improved physical function in idiopathic pulmonary fibrosis (IPF) patients treated with senolytic therapies. The trial was conducted by researchers at University of Texas Health ... Read more

December 21, 2018January 4, 2019

Mutation Prevents Mucus Clearance in Small Airways, Raising IPF Risk, Study Says

News

A study found a link between MUC5B-induced mucus accumulation and the progression of idiopathic pulmonary fibrosis, reporting that a MUC5B mutation can prevent mucus clearance in the small airways ... Read more

December 19, 2018December 19, 2018

FDA Approves the Launch of Clinical Trials to Assess IPF Candidate BBT-877

News

Bridge Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) recently approved the company’s Investigational New Drug (IND) application for BBT-877. The company now has permission to start human clinical ... Read more

December 12, 2018December 19, 2018

4MGS Test Predicts IPF Patient Mortality, Hospitalization, Study Says

News

Gait speed, measured by the four meter gait speed (4MGS) test, is an independent predictor of all-cause mortality and hospitalization in patients with idiopathic pulmonary fibrosis (IPF), according to ... Read more

December 10, 2018December 10, 2018

Veracyte Expands Early Access to Envisia Genomic Classifier Test for IPF Diagnosis

News

Veracyte recently announced the expansion of an early access program offering the Envisia Genomic Classifier test for the diagnosis of idiopathic pulmonary fibrosis (IPF). In the U.S., 20 medical centers ... Read more

December 4, 2018December 13, 2018

Late-stage IPF Patients Have Progressively Worse Quality of Life, Real-world Study Reports

News

Idiopathic pulmonary fibrosis (IPF) patients experience a significant decline in quality of life and worse symptom burden during the last months of life, a real-world study shows. The Finland-based ... Read more

Posts by: Santiago Gisler

Santiago Gisler

Black Tea Extract Reduced Fibrotic Features in PF Mouse Model

Interactive Platform Guides PF Patients, Connects Them with Healthcare Providers, Family

Actigraphy is Clinically Meaningful Tool in PH-IPF Patients Treated with iNOpulse

Oral IPF Candidate Targeting LOXL2 Protein May Move into Phase 2 Trials

Senolytic Treatment Improves Physical Function in IPF Patients, According to Small Pilot Study

Mutation Prevents Mucus Clearance in Small Airways, Raising IPF Risk, Study Says

FDA Approves the Launch of Clinical Trials to Assess IPF Candidate BBT-877

4MGS Test Predicts IPF Patient Mortality, Hospitalization, Study Says

Veracyte Expands Early Access to Envisia Genomic Classifier Test for IPF Diagnosis

Late-stage IPF Patients Have Progressively Worse Quality of Life, Real-world Study Reports

Pin It on Pinterest